Imago Biosciences

Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago's outstanding shares on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares.

Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatment of intermediate or high-risk MF.

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis

Bandwidth

CinCor Pharma

4D Molecular Therapeutics

GrowGeneration Corp

Nutex Health Inc

Silvergate Capital Corp

Vacasa

Veru

Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.

These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022

- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks —

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022

- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks -

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022

RAHWAY, N.J.--( BUSINESS WIRE )--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO). On Nov. 21, 2022, Merck announced that it had entered into a definitive agreement to acquire Imago.

Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.

Apollo Endosurgery

Graybug Vision

Salisbury Bancorp

NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Imago BioSciences, Inc. (NASDAQ: IMGO)'s  sale to Merck for $36.00 per share in cash. If you are an Imago shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IMGO, GRAY, APEN, SAL

Imago BioSciences becomes part of the Merck & Co., Inc. family for $1.35 billion. Imago BioSciences, Inc. will certainly strengthen Merck's position in hematology.

Imago BioSciences: The Bone Marrow Cancer Researcher Reaches Milestone

REDWOOD CITY, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory acute myeloid leukemia (AML). Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Imago BioSciences, Inc. (NasdaqGS: IMGO) to Merck (NYSE: MRK). Under the terms of the proposed transaction, shareholders of Imago will receive only $36.00 in cash for each share of Imago that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

IMAGO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Imago BioSciences, Inc. - IMGO

Imago BioSciences (IMGO) to be acquired by pharma-giant Merck (MRK) for $1.35 billion. The transaction is likely to close by first-quarter 2023.

Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck

NEW YORK , Nov. 21, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Imago BioSciences, Inc. ("Imago" or the "Company") (NASDAQ: IMGO), in connection with the tender offer for the Company by a subsidiary of Merck & Co., Inc. (NYSE: MRK). Under the tender offer terms, the Company's shareholders will receive $36.00 in cash for each share of Imago common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Imago BioSciences, Inc.

Wilmington, Delaware--(Newsfile Corp. - November 21, 2022) - Rigrodsky Law, P.A. is investigating Imago BioSciences, Inc. ("Imago") (NASDAQ: IMGO) regarding possible breaches of fiduciary duties and other violations of law related to Imago's agreement to be acquired by Merk Sharp & Dohme LLC. Under the terms of the agreement, Imago's shareholders will receive $36.00 per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-imago-biosciences-inc.To contact Seth D. Rigrodsky or Gina M.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Imago BioSciences, Inc. Buyout

MILWAUKEE , Nov. 21, 2022 /PRNewswire/ -- Ademi LLP is investigating Imago (Nasdaq: IMGO) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.  Click here to learn how to join the action https://www.ademilaw.com/case/imago-biosciences-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Imago BioSciences, Inc. has obtained a Fair Price in its transaction with Merck

Tesla

Markets sent mixed messages to start out Thanksgiving week.

As Tesla Sinks to 2-Year Lows, This Nasdaq Stock Just Doubled

Imago Biosciences (NASDAQ: IMGO ) stock is rocketing higher on Monday following news that Merck (NYSE: MRK ) is acquiring the company. Merch is going to spend $1.35 billion to buy Imago Biosciences.

Why Is Imago Biosciences (IMGO) Stock Up 105% Today?

Shares of Imago Biosciences Inc (NASDAQ: IMGO) opened more than 100% up this morning after Merck & Co Inc (NYSE: MRK) said it will acquire the biopharmaceutical firm in a $1.35 billion deal.

This biopharma stock more than doubled on Monday: find out more

Biotech stock Imago BioSciences broke out and hit a record high Monday after Merck pledged to buy it for $1.35 billion. The post Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout appeared first on Investor's Business Daily.

Imago BioSciences Catapults To Record High On Merck's $1.35 Billion Buyout

NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Imago BioSciences, Inc. (NASDAQ: IMGO) to Merck for $36.00 per share in cash is fair to Imago shareholders.

IMGO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Imago BioSciences, Inc. Is Fair to Shareholders

Merck & Co., Inc. (NYSE:MRK) is set to acquire biopharmaceutical company Imago Biosciences Inc (NASDAQ:IMGO) in a cash deal worth $1.35 billion.

Merck Making Moves, to Acquire Imago Biosciences

Merck (NYSE: MRK) announced it is buying Imago BioSciences (IMGO) for $1.35 billion. These are the details.

Why Merck (MRK) Is Buying Imago BioSciences (IMGO) For $1.35 Billion

Merck will pay $36 in cash for each share of Imago BioSciences.

Imago BioSciences Stock Surges. It's Being Bought by Merck.

Merck said it will pay $36 a share cash for Imago, which is developing drugs to treat bone-marrow diseases.

Merck Strikes $1.35 Billion Deal for Bone-Marrow Disease Drug Developer

Shares of Imago BioSciences Inc. IMGO, -3.87% soared toward an eight-month high in premarket trading Monday, after the biopharmaceutical company developing treatments for myeloproliferative neoplasms (MPNs) and other bone marrow diseases announced an agreement to be acquired by Merck & Co. Inc. MRK, +1.88% in a cash deal with a equity value of $1.35 billion. Under terms of the deal, Merck will pay $36.00 for each Imago share, which represents a 106.9% premium to Friday's closing price of $17.40.

Imago BioSciences stock soars after Merck bids more than 100% premium to buy the biotech

Merck & Co Inc said on Monday it would acquire cancer drug developer Imago BioSciences for a total equity value of $1.35 billion.

News for Imago Biosciences Stock (IMGO)